Related to It's Time to Break Your Silence about Workplace Discrimination

• FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion
  
• Phase III Data Shows Novartis’ Afinitor More Than Doubles PFS in Pancreatic NET Patients
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• FDA Okays Novartis’ Hypertension Combination Therapy
  
• Novartis and Collaborators Discover Candidate for Drug-Resistant Malaria
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• Novartis’ Onbrez Breezhaler Trumps Salmeterol in Phase III COPD Trial
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending
  
• Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Pivotal Study Finds Novartis Adjuvanted Flu Vaccine 89% Effective in Infants and Children
  
• sBLA Filing for Novartis' Menveo Vaccine in Infants Imminent after Positive Phase III Data
  
• Novartis’ Afinitor Cleared by FDA for Treating SEGA Tumors in Tuberous Sclerosis
  
• Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera
  
• Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs